Drug Search Results
More Filters [+]

Seletracetam

Alternative Names: seletracetam, ucb44212
Latest Update: 2024-03-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: SV2A Binder

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seletracetam

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Epilepsy|Epilepsies, Partial

Phase 2: Epilepsies, Partial

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

N01192

P2

Completed

Epilepsies, Partial

2006-05-12

N01191

P2

Completed

Epilepsies, Partial

2006-05-03

N01197

P3

Withdrawn

Epilepsy

None

N01272

P3

Withdrawn

Epilepsies, Partial

None

Recent News Events

Date

Type

Title